CALZ.F Stock Overview
PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 6/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
PolyNovo Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$1.44 |
| 52 Week High | AU$1.54 |
| 52 Week Low | AU$0.40 |
| Beta | 1.6 |
| 1 Month Change | -6.25% |
| 3 Month Change | 41.04% |
| 1 Year Change | 25.22% |
| 3 Year Change | -37.39% |
| 5 Year Change | 114.93% |
| Change since IPO | 105.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| CALZ.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | -2.9% | -3.1% |
| 1Y | 25.2% | 2.1% | 20.9% |
Return vs Industry: CALZ.F exceeded the US Medical Equipment industry which returned 3.1% over the past year.
Return vs Market: CALZ.F exceeded the US Market which returned 22.4% over the past year.
Price Volatility
| CALZ.F volatility | |
|---|---|
| CALZ.F Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 7.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CALZ.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine CALZ.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 237 | Swami Raote | www.polynovo.com |
PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; NovoSorb Dermal Beta Cell Implant to host pancreatic islet cells in the skin; NovoSorb MTX for the treatment of varying complex wounds; and plastics and reconstructive device product.
PolyNovo Limited Fundamentals Summary
| CALZ.F fundamental statistics | |
|---|---|
| Market cap | US$959.83m |
| Earnings (TTM) | US$1.03m |
| Revenue (TTM) | US$53.99m |
930.7x
P/E Ratio17.8x
P/S RatioIs CALZ.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CALZ.F income statement (TTM) | |
|---|---|
| Revenue | AU$83.47m |
| Cost of Revenue | AU$14.09m |
| Gross Profit | AU$69.38m |
| Other Expenses | AU$67.78m |
| Earnings | AU$1.59m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0023 |
| Gross Margin | 83.12% |
| Net Profit Margin | 1.91% |
| Debt/Equity Ratio | 3.4% |
How did CALZ.F perform over the long term?
See historical performance and comparison